

|                         |  |
|-------------------------|--|
| <b>NCT ID</b>           | NCT05194735  |
| <b>Title</b>            | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors  |
| <b>Phase</b>            | Phase 1  |
| <b>Date Added</b>       | 2022-01-18   |
| <b>Location</b>         | Texas, United States   |
| <b>Prior IO Allowed</b> | Yes  |
| <b>CRC-directed</b>     | Yes  |
| <b>Status</b>           | Active, not recruiting   |
| <b>Drugs</b>            | Aldesleukin (IL-2), Neoantigen specific TCR-T cell drug product  |
| <b>Tags</b>             | MSS/ MMRp  |
| <b>NCT ID</b>           | NCT05722327  |
| <b>Title</b>            | Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer   |
| <b>Phase</b>            | Phase 1  |
| <b>Date Added</b>       | 2023-02-10   |
| <b>Location</b>         | Texas, United States   |
| <b>Prior IO Allowed</b> | No   |
| <b>CRC-directed</b>     | Yes  |
| <b>Status</b>           | Active, not recruiting   |
| <b>Drugs</b>            | cetuximab, Irinotecan, MRTX849   |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp   |
| <b>NCT ID</b>           | NCT03772561  |
| <b>Title</b>            | Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies  |
| <b>Phase</b>            | Phase 1  |
| <b>Date Added</b>       | 2018-12-11   |
| <b>Location</b>         | Singapore  |
| <b>Prior IO Allowed</b> | No   |
| <b>CRC-directed</b>     | No   |
| <b>Status</b>           | Recruiting   |
| <b>Drugs</b>            | AZD5363+Olaparib+Durvalumab  |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp   |
| <b>NCT ID</b>           | NCT06105021  |
| <b>Title</b>            | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor   |
| <b>Phase</b>            | Phase 1, Phase 2   |
| <b>Date Added</b>       | 2023-10-27   |
| <b>Location</b>         | California, United States<br>Connecticut, United States<br>New York, United States<br>Oregon, United States<br>Tennessee, United States<br>Texas, United States<br>Washington, United States<br>Wisconsin, United States |
| <b>Prior IO Allowed</b> | Yes  |
| <b>CRC-directed</b>     | Yes  |
| <b>Status</b>           | Recruiting   |
| <b>Drugs</b>            | AFNT-211   |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp   |

---

|                  |  |
|------------------|--|
| NCT ID           | NCT06302062  |
| Title            | Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors |
| Phase            | Phase 1  |
| Date Added       | 2024-03-08   |
| Location         | China  |
| Prior IO Allowed | Yes  |
| CRC-directed     | No   |
| Status           | Recruiting   |
| Drugs            | Cyclophosphamide, IL-2, Serplulimab Injection, Tumor Associated Lymph node T cell              |
| Tags             | MSI-H/ MMRd, MSS/ MMRp   |

---

|            |  |
|------------|--|
| NCT ID     | NCT04793958  |
| Title      | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) |
| Phase      | Phase 3  |
| Date Added | 2021-03-11   |

|                         |                               |
|-------------------------|-------------------------------|
| <b>Location</b>         | Alabama, United States        |
|                         | Arizona, United States        |
|                         | Arkansas, United States       |
|                         | California, United States     |
|                         | Colorado, United States       |
|                         | Connecticut, United States    |
|                         | Florida, United States        |
|                         | Georgia, United States        |
|                         | Illinois, United States       |
|                         | Indiana, United States        |
|                         | Iowa, United States           |
|                         | Louisiana, United States      |
|                         | Maryland, United States       |
|                         | Massachusetts, United States  |
|                         | Michigan, United States       |
|                         | Minnesota, United States      |
|                         | Missouri, United States       |
|                         | Nebraska, United States       |
|                         | Nevada, United States         |
|                         | New Jersey, United States     |
|                         | New York, United States       |
|                         | North Carolina, United States |
|                         | Ohio, United States           |
|                         | Oklahoma, United States       |
|                         | Pennsylvania, United States   |
|                         | South Carolina, United States |
|                         | Tennessee, United States      |
|                         | Texas, United States          |
|                         | Utah, United States           |
|                         | Virginia, United States       |
|                         | Washington, United States     |
|                         | West Virginia, United States  |
|                         | Wisconsin, United States      |
|                         | Argentina                     |
|                         | Australia                     |
|                         | Austria                       |
|                         | Belgium                       |
|                         | Brazil                        |
|                         | Canada                        |
|                         | China                         |
|                         | Colombia                      |
|                         | Czechia                       |
|                         | Denmark                       |
|                         | Finland                       |
|                         | France                        |
|                         | Germany                       |
|                         | Greece                        |
|                         | Hong Kong                     |
|                         | Ireland                       |
|                         | Italy                         |
|                         | Korea, Republic of            |
|                         | Malaysia                      |
|                         | Mexico                        |
|                         | Netherlands                   |
|                         | Poland                        |
|                         | Portugal                      |
|                         | Puerto Rico                   |
|                         | Romania                       |
|                         | Singapore                     |
|                         | Spain                         |
|                         | Taiwan                        |
|                         | Thailand                      |
|                         | Ukraine                       |
|                         | United Kingdom                |
| <b>Prior IO Allowed</b> | Yes                           |
| <b>CRC-directed</b>     | Yes                           |

|                         |   |
|-------------------------|---|
| <b>Status</b>           | Active, not recruiting  |
| <b>Drugs</b>            | cetuximab, FOLFIRI Regimen, mFOLFOX6 Regimen, MRTX849   |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp  |
| <b>NCT ID</b>           | NCT06589440   |
| <b>Title</b>            | Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)   |
| <b>Phase</b>            | Phase 2   |
| <b>Date Added</b>       | 2024-09-19  |
| <b>Location</b>         | New Jersey, United States<br>Texas, United States<br>Washington, United States  |
| <b>Prior IO Allowed</b> | No  |
| <b>CRC-directed</b>     | Yes   |
| <b>Status</b>           | Recruiting  |
| <b>Drugs</b>            | Balstilimab, Botensilimab   |
| <b>Tags</b>             | MSS/ MMRp   |
| <b>NCT ID</b>           | NCT05480306   |
| <b>Title</b>            | Phase 2 Study of DKN-01 in Colorectal Cancer  |
| <b>Phase</b>            | Phase 2   |
| <b>Date Added</b>       | 2022-07-29  |
| <b>Location</b>         | Arizona, United States<br>California, United States<br>Florida, United States<br>Louisiana, United States<br>Maryland, United States<br>Missouri, United States<br>New York, United States<br>North Carolina, United States<br>South Carolina, United States<br>South Dakota, United States<br>Tennessee, United States<br>Washington, United States<br>Wisconsin, United States<br>Germany<br>Korea, Republic of |
| <b>Prior IO Allowed</b> | No  |
| <b>CRC-directed</b>     | Yes   |
| <b>Status</b>           | Active, not recruiting  |
| <b>Drugs</b>            | Bevacizumab, DKN-01, FOLFIRI, FOLFOX  |
| <b>Tags</b>             | MSS/ MMRp   |
| <b>NCT ID</b>           | NCT06039202   |
| <b>Title</b>            | Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer  |
| <b>Phase</b>            | Phase 2   |
| <b>Date Added</b>       | 2023-09-15  |
| <b>Location</b>         |   |
| <b>Prior IO Allowed</b> | Yes   |
| <b>CRC-directed</b>     | Yes   |
| <b>Status</b>           | Not yet recruiting  |
| <b>Drugs</b>            | CA102N, TAS-102   |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp  |

---

|                         |   |
|-------------------------|---|
| <b>NCT ID</b>           | NCT04046445   |
| <b>Title</b>            | Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer   |
| <b>Phase</b>            | Phase 1   |
| <b>Date Added</b>       | 2019-08-06  |
| <b>Location</b>         | Arizona, United States<br>California, United States<br>Colorado, United States<br>New York, United States<br>North Carolina, United States<br>Texas, United States<br>Belgium<br>Germany<br>Switzerland |
| <b>Prior IO Allowed</b> | No  |
| <b>CRC-directed</b>     | Yes   |
| <b>Status</b>           | Active, not recruiting  |
| <b>Drugs</b>            | ATP128, BI 754091, VSV-GP128  |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp  |